Trials / Recruiting
RecruitingNCT04837339
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- Sponsor
- Hopital Foch · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.
Conditions
- Lung Transplant Rejection
- Lung Transplant Failure
- Lung Transplant; Complications
- Lung Transplant Failure and Rejection
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Collection of biological samples | Blood sample, biopsies sample, hair sample. |
Timeline
- Start date
- 2022-03-17
- Primary completion
- 2037-03-01
- Completion
- 2037-03-01
- First posted
- 2021-04-08
- Last updated
- 2022-08-03
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04837339. Inclusion in this directory is not an endorsement.